Kyoto, Japan

Hidetaka Fujihara

This inventor holds 2 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Nippon Shinyaku Company, Ltd.. Active years: 2013-2014.

USPTO Granted Patents = 2 

% Patents Active = 50.0


 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2013-2014

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Hidetaka Fujihara: Innovator in Aminopyrazine Derivatives

Introduction

Hidetaka Fujihara is a notable inventor based in Kyoto, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of aminopyrazine derivatives. His work has led to the filing of multiple patents, showcasing his innovative approach to pharmaceutical compounds.

Latest Patents

Hidetaka Fujihara holds 2 patents related to aminopyrazine derivatives and their medicinal applications. His latest patents describe a compound represented by a general formula that satisfies specific criteria, including various substituents such as halogen atoms and alkyl groups. These compounds are designed to be pharmaceutically acceptable, highlighting their potential use in medical treatments.

Career Highlights

Fujihara is currently employed at Nippon Shinyaku Company, Ltd., where he continues to advance his research in pharmaceutical sciences. His work is characterized by a commitment to innovation and the development of new therapeutic agents.

Collaborations

Throughout his career, Hidetaka Fujihara has collaborated with esteemed colleagues, including Tetsuo Asaki and Katsutoshi Hori. These partnerships have fostered a collaborative environment that enhances the research and development of new medicinal compounds.

Conclusion

Hidetaka Fujihara's contributions to the field of medicinal chemistry through his patents and collaborations underscore his role as an influential inventor. His work continues to pave the way for advancements in pharmaceutical science.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…